The actual numbers are almost irrelevant - what is more important (and would have more impact on the PPS) is projections.
Specifically if they talk about fixing Forfivo. They need to stop talking about capturing less than half of the measly $200M a year high dose Bupropion market - and instead announce a new marketing focus that targets the whole AD market (which is a multi-Billion dollar pond).
Bupropion is superior to virtually all other AD drugs in secondary consumer benefits. All the other AD drugs tend to cause weight gain and loss of sexual desire - Bupropion is exactly the opposite. It has been used for decades as a smoking cessation drug, and shown that it can at the same time reduce your appetite. Other independent studies have shown an increase in sexual desire in women who have used Bupropion.
It is utterly amazing to me just how f-ing stupid Zerbe once he takes that lab coat off.
News 
Market Data 
Discover 
